Dandelion Launches GLP-1 Data Library for Cardiometabolic Insights

Dandelion Health has introduced a groundbreaking multimodal, real-world clinical dataset designed to offer new insights and opportunities for enhancing the treatment of cardiometabolic diseases through GLP-1 receptor agonist drugs. This dataset, compiled from a consortium of non-academic medical center health system partners, contains longitudinal patient information from millions of individuals.

Shivaani Prakash, Dandelion's head of data, emphasized the dataset's capability to address critical questions regarding the role of GLP-1 based treatments in clinical settings. Prakash highlighted the company's goal to curate a comprehensive dataset that encapsulates the extensive benefits of these emerging treatments, drawing from a more extensive and representative patient population than typically seen in traditional clinical trials.

Updated quarterly, Dandelion's data library amalgamates data from the entire patient journey. This includes structured electronic health record (EHR) data alongside all raw clinical data generated during treatments, such as radiology images, ECG waveforms, and clinical notes. The library allows research organizations to assess the quality of weight loss through biomarkers seen in body scans, compare the efficacy of treatments across various real-world metrics, and highlight the therapeutic effects of the drugs beyond current uses. These effects include secondary benefits discovered through exploratory use or verified with additional data modalities.

Moreover, the dataset can be utilized to measure side effects associated with GLP-1 drugs and to develop tools for identifying patients with uncontrolled symptoms, ensuring they receive appropriate treatment plans.

Dandelion is already collaborating with several AI developers and researchers to pioneer proofs of concept using its GLP-1 data library. One initiative involves researchers at a significant academic medical center who have created an algorithm to segment abdominal CT scans, quantify fat loss, and evaluate muscle and bone preservation. This algorithm aims to assess the impact of GLP-1s on overall body composition.

Additionally, Dandelion has conducted its internal research using the library's EHR data to assess the drugs' efficacy across real-world patient cohorts and demographic groups. The research also explores the relationship between treatment duration, clinical outcomes, and observable effects of GLP-1 on other comorbidities, which may indicate potential adjacent indications. The startup intends to publish its findings in a scientific preprint in the second quarter.